Drug-induced torsade de pointes - PubMed (original) (raw)
Review
. 1985 Nov-Dec;4(6):675-90.
- PMID: 2416504
Review
Drug-induced torsade de pointes
C L Raehl et al. Clin Pharm. 1985 Nov-Dec.
Abstract
Three patients who developed torsade de pointes associated with antiarrhythmic or psychotropic drugs are described, and the electrocardiographic characteristics, clinical presentation, predisposing factors, and management of this form of ventricular tachycardia are reviewed. The first patient was a 56-year-old schizophrenic man receiving thioridazine hydrochloride, trifluoperazine hydrochloride, and benztropine mesylate who was admitted to a hospital after a syncopal episode. Subsequently, the patient experienced several episodes of ventricular tachycardia combined with multifocal premature ventricular contractions (PVCs) and torsade de pointes; the arrhythmias were attributed to antipsychotic therapy. The second patient was a 69-year-old man who experienced ventricular tachycardia that progressed to ventricular fibrillation 41 days after surgery. Quinidine sulfate probably induced the ventricular tachycardia, which was identified as torsade de pointes. The third patient was a 71-year-old man admitted to the hospital for treatment of refractory ventricular arrhythmias. Previous drug therapy with quinidine sulfate and procainamide hydrochloride had been associated with torsade de pointes. Despite unsuccessful treatment of ventricular ectopy, the patient was discharged on maintenance therapy with pindolol, topical nitrates, and phenytoin. No additional episodes of torsade de pointes have been observed. Torsade de pointes is characterized by polymorphous electrocardiographic appearance and delayed repolarization (prolonged QT interval). It may occur in association with a number of disease states and also as a complication of treatment with therapeutic doses of drugs that affect repolarization (quinidine, disopyramide, procainamide, and phenothiazines). Clinical outcomes range from asymptomatic, self-terminating arrhythmias to ventricular fibrillation resulting in cardiac arrest. The definitive emergency therapy for torsade de pointes is overdrive pacing; cautious isoproterenol administration can also be used. Lidocaine and bretylium are often ineffective in treating this form of ventricular tachycardia. Potassium and magnesium repletion appear to be essential in abolishing drug-induced torsade de pointes. Drug-induced torsade de pointes is best prevented by avoiding agents known to induce arrhythmias in patients with a pre-existing prolonged QT interval. Periodic serum electrolyte assessment is warranted, and new drugs that prolong the QT interval should be considered potential causative agents of torsade de pointes.
Similar articles
- [Iatrogenic torsade de pointes induced by thioridazine].
Paoloni P, Ciliberti D, Blasi N, Capone P. Paoloni P, et al. Minerva Cardioangiol. 1992 Jun;40(6):245-9. Minerva Cardioangiol. 1992. PMID: 1407620 Italian. - Disopyramide-induced Torsade de Pointes.
Tzivoni D, Keren A, Stern S, Gottlieb S. Tzivoni D, et al. Arch Intern Med. 1981 Jun;141(7):946-7. Arch Intern Med. 1981. PMID: 7235820 - Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
Skanes AC, Morton BC, Green MS, Tang AS. Skanes AC, et al. Can J Cardiol. 1997 Apr;13(4):383-6. Can J Cardiol. 1997. PMID: 9141970 Review. - [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
Lentini S, Rao ML, Schröder R, Lüderitz B, Bauriedel G. Lentini S, et al. Dtsch Med Wochenschr. 2001 Dec 7;126(49):1396-400. doi: 10.1055/s-2001-18880. Dtsch Med Wochenschr. 2001. PMID: 11740632 German.
Cited by
- Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres.
Champeroux P, Viaud K, El Amrani AI, Fowler JS, Martel E, Le Guennec JY, Richard S. Champeroux P, et al. Br J Pharmacol. 2005 Feb;144(3):376-85. doi: 10.1038/sj.bjp.0706070. Br J Pharmacol. 2005. PMID: 15655517 Free PMC article. - The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia.
Dallmann R, Weyermann P, Anklin C, Boroff M, Bray-French K, Cardel B, Courdier-Fruh I, Deppe H, Dubach-Powell J, Erb M, Haefeli RH, Henneböhle M, Herzner H, Hufschmid M, Marks DL, Nordhoff S, Papp M, Rummey C, Santos G, Schärer F, Siendt H, Soeberdt M, Sumanovski LT, Terinek M, Mondadori C, Güven N, Feurer A. Dallmann R, et al. J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):163-174. doi: 10.1007/s13539-011-0039-1. Epub 2011 Aug 28. J Cachexia Sarcopenia Muscle. 2011. PMID: 21966642 Free PMC article. - Impaired Inactivation of L-Type Ca2+ Current as a Potential Mechanism for Variable Arrhythmogenic Liability of HERG K+ Channel Blocking Drugs.
Kim JG, Sung DJ, Kim HJ, Park SW, Won KJ, Kim B, Shin HC, Kim KS, Leem CH, Zhang YH, Cho H, Bae YM. Kim JG, et al. PLoS One. 2016 Mar 1;11(3):e0149198. doi: 10.1371/journal.pone.0149198. eCollection 2016. PLoS One. 2016. PMID: 26930604 Free PMC article. - On the potential of in vitro organ-chip models to define temporal pharmacokinetic-pharmacodynamic relationships.
McAleer CW, Pointon A, Long CJ, Brighton RL, Wilkin BD, Bridges LR, Narasimhan Sriram N, Fabre K, McDougall R, Muse VP, Mettetal JT, Srivastava A, Williams D, Schnepper MT, Roles JL, Shuler ML, Hickman JJ, Ewart L. McAleer CW, et al. Sci Rep. 2019 Jul 3;9(1):9619. doi: 10.1038/s41598-019-45656-4. Sci Rep. 2019. PMID: 31270362 Free PMC article. - In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials.
Borsini F, Crumb W, Pace S, Ubben D, Wible B, Yan GX, Funck-Brentano C. Borsini F, et al. Antimicrob Agents Chemother. 2012 Jun;56(6):3261-70. doi: 10.1128/AAC.05688-11. Epub 2012 Mar 5. Antimicrob Agents Chemother. 2012. PMID: 22391528 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources